Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • US debt crisis: Joe Biden gets the deal done but at a cost
    • Erdoğan extends rule into third decade with Turkish election victory
    • Republican leaders try to quell debt deal revolt as US counts down to default
    • China’s first passenger jet completes maiden commercial flight
    • Russia launches massive drone attack on Kyiv
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Mike Lynch uses $50mn in Darktrace shares to secure US bail
      • Canada’s big banks log 13-fold rise in loan loss provisions
      • Sky to cut hundreds of jobs in shift from satellite TV
      • UK mid-market dining chains fight for survival after Covid and cost of living woes
      • Peter Orszag: the ‘scholar-banker’ aiming to restore Lazard’s fortunes
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Après debt ceiling deal, le T-bill déluge
      • AI boom drives gains for chip stocks
      • India’s biggest alternative asset manager bets on private credit
      • A European People’s Bond could support Ukraine’s reconstruction
      • Is COP28 destined to be a flop?
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • How to buy a global $20bn company for nothing
      • Now the UK is finally tackling ‘Londongrad’, it’s time the US upped its game
      • Citizens’ juries can help fix democracy
      • Taking an electric car on the road is still a gamble in America
      • What we get wrong about ageing and work
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • ‘Everyone has the right to completely log off’: what bosses think about the right to disconnect
      • Wellcome Leap’s Regina Dugan: ‘Odds are irrelevant, if what you’re trying to do is important’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Yes, Suella Braverman should go, but not for the reason you think
      • The UK’s best bakeries: the readers’ picks
      • GCHQ’s Jeremy Fleming: ‘Xi doesn’t want to see Putin humiliated’
      • The Michelin-starred McMuffin...
      • From Bowie to Jagger, the photos that created legends
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Illumina Inc

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Saturday, 27 May, 2023
      Illumina accused by Brussels of ‘delay tactics’ on Grail divestiture

      World’s biggest gene sequencing company rejects EU’s fast- track application

    • Thursday, 25 May, 2023
      Illumina chair ousted in proxy battle with Carl Icahn

      Vote to remove John Thompson is the culmination of one of the largest shareholder activism campaigns in years

    • Wednesday, 24 May, 2023
      Interview
      Illumina can survive loss of chair and CEO, says board director

      Gene sequencing company heads for pivotal vote in battle with activist investor Carl Icahn

    • Wednesday, 10 May, 2023
      Glass Lewis backs Carl Icahn’s push to oust Illumina’s chief and chair

      Proxy adviser says the two executives failed to take responsibility for destructive deal for Grail

    • Tuesday, 4 April, 2023
      Illumina battle with regulators threatens cancer breakthrough, warn Grail alumni

      Founding directors say political wrangling causing delays to potentially life-saving blood test

    • Monday, 3 April, 2023
      Mergers & Acquisitions
      US antitrust regulator orders Illumina to unwind $8bn Grail deal

      FTC warns acquisition would hurt competition in the market for early detection cancer tests

    • Thursday, 30 March, 2023
      Illumina chief’s pay nearly doubles ahead of clash with Carl Icahn

      Francis deSouza was awarded $26.7mn in total pay last year despite drop in genome sequencer’s market value

    • Friday, 24 March, 2023
      Carl Icahn says Illumina directors demanded extra insurance for Grail deal

      Activist investor steps up battle over ‘disastrous’ acquisition by world’s biggest genome sequencer

    • Friday, 17 March, 2023
      InterviewCarl Icahn
      Carl Icahn urges Fed to keep fighting inflation ‘disease’

      Comments by activist investor come ahead of US central bank’s rate-setting meeting next week

    • Monday, 13 March, 2023
      Carl Icahn takes aim at genome sequencer Illumina over Grail deal

      Company’s shares jump after activist investor launches proxy battle

    • Tuesday, 7 February, 2023
      Health sector
      Illumina boosts spending on US lobbying amid opposition to Grail acquisition

      Genome sequencing company paid firms $14.6mn over past two years to try to sway lawmakers

    • Sunday, 29 January, 2023
      News in-depth
      Has Illumina taken the wrong path in its Grail quest?

      DNA sequencing expert’s investors question acquisition of cancer testing group that has also angered EU regulators

    • Monday, 5 September, 2022
      Illumina to challenge Brussels over any block on Grail merger

      US biotech to object to impending EU ruling on $8bn deal for cancer screening group

    • Thursday, 1 September, 2022
      Illumina wins battle against US regulators trying to block $8bn Grail deal

      Setback for FTC after administrative law judge gives nod to acquisition of cancer testing group

    • Wednesday, 13 July, 2022
      EU business regulation
      EU court ruling expands Brussels’ powers to scrutinise tech mergers

      Ruling allows European probe of Illumina’s $8bn Grail takeover and sets precedent for deeper oversight of deals

    • Sunday, 16 January, 2022
      Illumina says EU probe of $8bn Grail deal could hit biotech investment

      Chief executive deSouza attacks regulatory intervention over cancer test company

    • Wednesday, 18 August, 2021
      Illumina pushes ahead with closing $8bn Grail merger in defiance of EU probe

      US biotech takes aggressive step over cancer-screening deal fearing Brussels review will not beat deadline

    • Wednesday, 14 July, 2021
      Brooke Masters
      Competition enforcement is harder than it looks

      Novel antitrust cases complicate efforts to tackle climate change and healthcare

    • Tuesday, 1 June, 2021
      Illumina accuses US regulators of time-wasting over $8bn Grail deal

      Biotech group’s chief warns lives will be at risk if approval process is delayed

    • Thursday, 29 April, 2021
      Illumina sues Brussels over probe into $8bn cancer deal for Grail

      US genomics company takes rare step after authorities indicate they will review the deal

    • Wednesday, 31 March, 2021
      Lex
      Illumina: vertical acquisition in the crosshairs Premium content

      Competition regulator’s move on Grail purchase confirms era of bolder antitrust bodies

    • Tuesday, 23 February, 2021
      Genomics
      Genomic sequencing head calls for ‘Bio Force’ to detect virus threats

      Illumina’s Francis De Souza says global co-operation needed to keep up with new strains

    • Monday, 21 September, 2020
      Biotech
      Illumina agrees $8bn deal for cancer screening group Grail

      Genetic sequencing company set to take full ownership of start-up

    • Friday, 3 January, 2020
      Pharmaceuticals sector
      Illumina and Pacific Biosciences call off merger

      Mooted $1.2bn deal halted after scrutiny by UK and US competition watchdogs

    • Monday, 30 July, 2018
      Technology sector
      Illumina shares lit up by earnings beat, outlook raise
    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsFT Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In